ST
stuart_roberts
Community Contributor
Followers0Total number of followers
Comments0Total number of comments
Member Since2025Date joined
Life sciences equity analyst with a passion for biotech and healthcare investing. Founder of NDF Research and co-founder of Pitt Street Research, known for turning complex science and technology into clear, investable ideas
https://pittstreetresearch.com/
Unicycive Therapeutics (Nasdaq: UNCY) – Preparing for a Second Shot at Bringing a New Kidney Treatment to Market (TEST)
Key Takeaways Unicycive has completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC is designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability for dialysis patients with hyperphosphatemia.Read more
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
ST
US$21.53
70.2% undervalued intrinsic discount
stuart_roberts's Fair Value
Profit Margin
20.04%
Future PE
27.62x
Price in 2030
US$34.68